First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients. Methods: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. Results: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7–24.3) and 85.4% (95% CI: 58.1–73.6) vs. 41.7% (95% CI: 34.2–51.0). Conclusions: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics

Legibility research 1972 - 1978: A summary

7.70SIGLELD:f81/0070 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

A Highly Modular Scientific Nanosatellite: TEST

A powerfully instrumented, reliable, low-cost 3-axis stabilized nanosatellite is in final design using novel technologies. The Thunderstorm Effects in Space: Technology (TEST) nanosatellite implements a new, highly modular satellite bus structure and common electrical interface that is conducive to satellite modeling, development, testing, and integration flow. TEST is a low-cost ($0.1 – 0.2 M) nanosatellite (30kg) in final development by Taylor University and the University of Illinois through the Air Force Office of Space Research (AFOSR) University Nanosatellite program. TEST implements a strong variety of plasma, energetic particle, and remote sensing instrumentation with the objective of understanding how lighting and thunderstorms influence the upper atmosphere and the near-space environment. As a disruptive technology, the TEST modular design and instrumentation challenges portions of satellite systems (such as future DOD DMSP and NASA LWS Geospace Missions), while complementing large multi-probe and remote sensing programs. TEST includes a variety of proven instrumentation: two 1m Electric Field (EP) probes, a thermal plasma density Langmuir Probe (LP), a 0.5 to 30 kHz Very Low Frequency (VLF) Receiver, two large geometric factor cooled (-60° C) Solid State Detector (SSD) spectrometers for energetic electrons and ions (10 keV \u3c E \u3c 1 MeV), a 3-axis Magnetometer (MAG), a O2 Hertzberg UV Photometer, a 391.4 nm Transient Photometer and a 630 nm Imager for airglow and lightning measurements. In addition, the satellite is three-axis stabilized using CO2 band horizon sensors, as well as a twostage passive radiator for instrument cooling. TEST instrumentation and satellite subsystems are packaged in modular cubes of 4in increments (CubeSat3)

Does merger mean integration? Scottish Natural Heritage and the Carin Gorm Funicular Application

SIGLEAvailable from British Library Document Supply Centre-DSC:7752.0071(68) / BLDSC - British Library Document Supply CentreGBUnited Kingdo